Nanomedicine:纳米载体跨越血脑屏障靶向治疗脑癌

2016-06-01 佚名 生物谷

(图片摘自www.sciencealert.com) 最近,科学家们在探索脑癌治疗手段的路上又有了新的突破。起初他们认为这一发现可能是一个测量错误,但事实证明该结果是真实的,而且将对脑癌的治疗产生巨大的影响。 通过利用纳米载体将化学药物定向运输到大脑中,科学家们能够将脑部的肿瘤细胞大量杀灭。 目前该技术仅仅在小鼠水平得到了验证,但如果能够同样适用于人体的话,将会导致新的治疗脑癌的疗法的产

(图片摘自www.sciencealert.com)

最近,科学家们在探索脑癌治疗手段的路上又有了新的突破。起初他们认为这一发现可能是一个测量错误,但事实证明该结果是真实的,而且将对脑癌的治疗产生巨大的影响。

通过利用纳米载体将化学药物定向运输到大脑中,科学家们能够将脑部的肿瘤细胞大量杀灭。

目前该技术仅仅在小鼠水平得到了验证,但如果能够同样适用于人体的话,将会导致新的治疗脑癌的疗法的产生。

该研究的首席科学家,来自南卡罗林娜医科大学的放射学家Ann-Marie Broome利用该技术靶向治疗成胶质细胞瘤(GBM, 一种目前难以治愈的癌症)。

由于位置特殊,常规的手段难以达到清除癌细胞的目的,而且由于血脑屏障的存在,将药物运送到脑部也没有那么容易。

这一新的纳米技术正是能够解决这一问题。Broome等人根据对GBM的了解以及能够调节细胞生长分裂的血小板生长因子(PDGF)制作出了纳米载体药物,载体骨架主要是由许多分子聚合形成的。

这个胶囊状的载体体型微小,能够轻易地跨越血脑屏障。研究者们描述:“胶囊能够将药物运送到正确的街道,而PDGF则能够将药物送到正确的房子里”。

 “这一新的纳米载体疗法的治疗效率奇高,令我也十分惊讶”,Broome说道:“通过优化,我们能够将任何化学药物特异性地运送到指定的病灶”。

 “这一技术能极大地提高我们对脑癌的治愈率,同时避免很多化疗带来的副作用。想像一下,未来有一天癌症也许不再危及生命,而且治愈过程不会感到痛苦,头发也能够保全”。

脑部肿瘤的特性给与了胶囊化的纳米载体以治疗潜力。当肿瘤生长时,将会向血液中释放一系列的副产物,这将会激活胶囊释放药物。

 令大众意识到纳米科技的潜在应用能力是十分重要的”,Broome说道。“它影响了许多领域,包括癌症。尤其是那些难以接近,难以治疗,难以进行药物处理的癌症类型”。

相关结果发表在nanomedicine杂志上。

原始出处:

Miller K, Dixit S et al.Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine.2016 Mar 22.


 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-07-01 mei539
  2. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2017-01-10 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2017-01-18 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 mym86538653

    什么时候用于患者

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1645421, encodeId=46d01645421d2, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Fri Jul 01 10:32:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858678, encodeId=85cb18586e833, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Jan 10 11:32:00 CST 2017, time=2017-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773550, encodeId=76791e735503e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Jan 18 10:32:00 CST 2017, time=2017-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075747, encodeId=01b620e574772, content=<a href='/topic/show?id=2022e74603e' target=_blank style='color:#2F92EE;'>#纳米载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77460, encryptionId=2022e74603e, topicName=纳米载体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Mon Dec 12 00:32:00 CST 2016, time=2016-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262326, encodeId=eafb126232639, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391864, encodeId=d9ec139186427, content=<a href='/topic/show?id=085c8495615' target=_blank style='color:#2F92EE;'>#脑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84956, encryptionId=085c8495615, topicName=脑癌)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKQHWdlyPWPmuHjfEXicudmC0dJ6SN5PHzglbDHibXpT1VXF2fKDnTzl2Eib4Pf94p58cnSKA3ZfGdFQ/132, createdBy=c44f2500101, createdName=ms2694732865965676, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577475, encodeId=c39215e74757d, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606936, encodeId=55141606936dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 03 05:32:00 CST 2016, time=2016-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88209, encodeId=57558820914, content=什么时候用于患者, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=61191606034, createdName=mym86538653, createdTime=Thu Jun 02 07:12:00 CST 2016, time=2016-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=88193, encodeId=78818819305, content=新的发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Jun 02 06:29:00 CST 2016, time=2016-06-02, status=1, ipAttribution=)]
    2016-06-02 老段

    新的发展

    0